South Korea, US Discuss Chip Investments Amid Tariff Plans 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Milei Threatens Falkland Oil Firms With Sanctions 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Anthropic IPO Marketing Expected to Start in Mid-October 
Add as a preferred source on Google
AUSTIN, Texas, Feb. 28, 2018 -- Vermillion, Inc. (Nasdaq:VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that it will report its fourth quarter and fiscal year ended December 31, 2017 financial results on Tuesday, March 13, 2018, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time.
Tuesday, March 13th @ 4:30 p.m. Eastern Time
| Domestic: | 800-281-7973 | |
| International: | 323-794-2093 | |
| Conference ID: | 5103935 | |
| Webcast: | http://public.viavid.com/index.php?id=128359 | |
| Replays, Available through March 27: | ||
| Domestic: | 844-512-2921 | |
| International: | 412-317-6671 | |
| Replay PIN: | 5103935 | |
About Vermillion
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with serious diseases. The company's initial in vitro diagnostic test, OVA1® (MIA), was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016, Vermillion received FDA clearance for Overa™, a Multivariate Index Assay 2nd Generation (MIA2G) test with significantly improved specificity and ease of use. For additional information, including published clinical trials, visit www.vermillion.com.
Investor Relations Contact:
Jeremy Feffer
LifeSci Advisors LLC
Tel 212-915-2568
[email protected]
